News >

Updates Continue in Oncogene-Driven Lung Cancer

Caroline Seymour
Published: Thursday, Aug 16, 2018

lung cancer
Targeted therapies ensure more durable responses, better overall responses, and lower toxicity than historical therapy for patients whose tumors harbor oncogenic drivers, such as EGFR, ALK, ROS1, and BRAF, though questions remain on their placement beyond progression.

, and stressed the significance of molecular testing.

OncLive: What are some of the updates with oncogene-driven NSCLC that you shared?

Pacheco: For my presentation, I spoke about the established genetic alterations for which we have approved targeted therapies. Those include EGFR activating mutations, ALK fusions, ROS1 fusions, and BRAF V600E mutations. We saw data from the FLAURA study presented within the past year suggesting that first-line osimertinib provides a PFS benefit for patients with traditional EGFR activating mutations; those include exon 19 deletions and L858R point mutations in exon 21. The PFS benefit for osimertinib compared with gefitinib or erlotinib was [nearly] 19 months versus 10 months.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Experts Weigh-In on Emerging Immune Checkpoint Inhibitors and Combination Strategies for Advanced NSCLCNov 30, 20191.5
Burst CME™ – Cancer Summaries and Commentaries: Update from Toronto: Advances in the Treatment of Lung CancersNov 30, 20190.5
Publication Bottom Border
Border Publication
x